BMRA vs PATH · rev $5.3M vs P/E 19, rev $1.61B
Biomerica Inc (BMRA) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Biomerica Inc (BMRA) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported BMRA revenue for 2025-05-31 was $5.3M. Net income was -$5.0M. Revenue was down 1.9% from 2024-05-31 to 2025-05-31. BMRA currently screens at market cap $8.0M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
BMRA currently screens at market cap $8.0M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the BMRA and PATH stock pages for the full models.
Not investment advice.